OmniSentrix

Every 40 seconds, someone in the United States suffers a heart attack. Yet, the standard ECG, still the first-line diagnostic tool, misses up to 50% of heart attacks, the most common type of heart attack, caused by a partial blockage. As a result, critical patient care is delayed, directly diminishing patient outcomes and putting lives at risk.

We are developing a high-sensitivity, point-of-care Troponin test that delivers lab-quality results in minutes either at the bedside, in the ambulance, or in a rural clinic hours from the nearest hospital. No cold-chain storage. No laboratory dependency. Unlike current alternatives, our device is engineered to perform at any temperature, in any environment, without compromise.

No heart attack should go undetected because of where a patient happens to be.